SERPING1 and hereditary angioedema: Icatibant was the most commonly used on‐demand treatment for HAE attacks (n = 5/7; 71%), with plasma‐derived C1‐inhibitor (n = 1/7; 14%) and recombinant C1‐inhibitor (n = 1/7; 14%) also used.